Lilly direct-selling Zepbound at $499/mo — compare with 11 other programs →
glpzoom

What GLP-1 is best for weight loss in 2026?

Reviewed by the glpzoom Editorial Team against primary clinical sources — FDA labeling, peer-reviewed trials, and specialty-society guidelines.
Content current as of June 2026; updated when guidance or availability changes.
Two GLP-1 medications are FDA-approved specifically for chronic weight management as of 2026: Wegovy (semaglutide 2.4mg weekly) and Zepbound (tirzepatide up to 15mg weekly). Saxenda (liraglutide, daily injection) is also approved but is older and produces less weight loss; most clinicians no longer start patients on it. Head-to-head: Zepbound produces more average weight loss in trials (~20% vs ~15%), confirmed in the SURMOUNT-5 study. Wegovy has a slightly longer real-world track record. Cost: Zepbound is often cheaper (LillyDirect Self-Pay vials $349-549/mo vs Wegovy NovoCare $499/mo). For most patients with no insurance constraint, Zepbound is the evidence-based first choice. For patients whose insurance covers only Wegovy (or only Saxenda), the right choice is whichever is covered. Compounded semaglutide is no longer broadly legal as of 2026. Off-label Ozempic and Mounjaro for weight loss exist but are typically not insurance-covered for non-diabetic patients.

Where to start

Licensed US telehealth services that handle this. We may earn a commission when you sign up. See disclosure.

  • Ro logo

    Ro

    from $145/mo
    • Best for insured patients
    • Best for clinical oversight

    Ro Body — branded GLP-1 weight care program

    Visit Ro →Read review
  • Hims logo

    Hims

    from $199/mo
    • Best for cash-pay
    • Best for speed

    Hims Weight Loss — compounded GLP-1 from $199/mo

    Visit Hims →Read review
  • Noom Med logo

    Noom Med

    from $179/mo
    • Best for coaching
    • Best for maintenance

    Noom Med — GLP-1 + behavioral psychology coaching

    Visit Noom Med →Read review

Drugs referenced

Related questions

  • Is Zepbound better than Wegovy?

    Zepbound (tirzepatide) shows greater average weight loss than Wegovy (semaglutide) in clinical trials — roughly 20% body weight loss vs 15% over similar time periods, including the head-to-head SURMOUNT-5 study where Zepbound's edge was confirmed. By that single metric, Zepbound is more effective on average. But 'better' for any individual patient depends on

  • Wegovy vs Zepbound: which is more effective?

    In separate Phase 3 trials, Zepbound (tirzepatide 15mg) produced ~20% mean body weight loss vs Wegovy (semaglutide 2.4mg) at ~15%. A head-to-head trial (SURMOUNT-5) confirmed Zepbound's edge. That said, individual response varies widely: some patients lose more on semaglutide than tirzepatide, others tolerate one's side-effect profile better than the other.

  • Is Wegovy or Zepbound cheaper?

    At list price, Zepbound is slightly cheaper than Wegovy (~$1,060 vs ~$1,349/month). For cash-pay patients, Lilly's self-pay vial program ($349-$549/month for Zepbound) tends to undercut Novo's NovoCare self-pay program ($499/month for Wegovy) at lower doses. At higher Zepbound doses, the gap narrows. Insurance coverage patterns are similar; the better choice

We may earn a commission when you click links to partners. Affiliate disclosure.